Safety of Paclitaxel-coated Devices in the Femoropopliteal Arteries: A Systematic Review and Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2022 Oct 13

PMID 36227807

Authors

Chenyang Zhang

Guosheng Yin

Affiliations

Soon will be listed here.

Abstract

Background: Clinical benefit of paclitaxel-coated devices for patients with peripheral arterial disease has been confirmed in randomized controlled trials (RCTs). A meta-analysis published in 2018 identified late mortality risk over a long follow-up period due to use of paclitaxel-coated devices in the femoropopliteal arteries, which caused enormous controversy and debates globally. This study aims to further evaluate the safety of paclitaxel-coated devices by incorporating the most recently published data.

Methods: We searched for candidate studies in PubMed (MEDLINE), Scopus, EMBASE (Ovid) online databases, government web archives and international cardiovascular conferences. Safety endpoints of interest included all-cause mortality rates at one, two and five years and the risk ratio (RR) was used as the summary measure. The primary analysis was performed using random-effects models to account for potential clinical heterogeneity.

Findings: Thirty-nine RCTs including 9164 patients were identified. At one year, the random-effects model yielded a pooled RR of 1.06 (95% CI [0.87, 1.29]) indicating no difference in short-term all-cause deaths between the paclitaxel and control groups (crude mortality, 4.3%, 214/5025 versus 4.5%, 177/3965). Two-year mortality was reported in 26 RCTs with 382 deaths out of 3788 patients (10.1%) in the paclitaxel arm and 299 out of 2955 patients (10.1%) in the control arm and no association was found between increased risk of death and usage of paclitaxel-coated devices (RR 1.08, 95% CI [0.93, 1.25]). Eight RCTs recorded all-cause deaths up to five years and a pooled RR of 1.18 (95% CI [0.92, 1.51]) demonstrated no late mortality risk due to use of paclitaxel-coated devices (crude mortality, paclitaxel 18.2%, 247/1360 versus control 15.2%, 122/805).

Conclusions: We found no significant difference in either short- or long-term all-cause mortalities between patients receiving paclitaxel-coated and uncoated devices. Further research on the longer-term safety of paclitaxel usage (e.g., 8- or 10-year) is warranted.

Registration: PROSPERO, CRD42021246291.

Citing Articles

Comparison of clinical outcomes of drug-coated balloons angioplasty vs. plain old balloons angioplasty for peripheral arterial disease: an umbrella meta-analysis.

Li J, Lu W, Lin L, Wu J, Cheng G, Hu Q Front Cardiovasc Med. 2024; 11:1511268.

PMID: 39639978 PMC: 11617568. DOI: 10.3389/fcvm.2024.1511268.

Drug-eluting devices for lower limb peripheral arterial disease.

Goueffic Y, Brodmann M, Deloose K, Dubosq-Lebaz M, Nordanstig J EuroIntervention. 2024; 20(18):e1136-e1153.

PMID: 39279515 PMC: 11423351. DOI: 10.4244/EIJ-D-23-01080.

Safety and Effectiveness of Passeo-18 Lux Drug-Coated Balloon Catheter in Infrainguinal Endovascular Revascularization in the Korean Population: A Multicenter Post-Market Surveillance Study.

Choi T, Won J, Jae H, Jeon Y, Park S, Ko G Korean J Radiol. 2024; 25(6):565-574.

PMID: 38807338 PMC: 11136951. DOI: 10.3348/kjr.2024.0099.

References

Xu Y, Liu J, Zhang J, Zhuang B, Jia X, Fu W . Long-term safety and efficacy of angioplasty of femoropopliteal artery disease with drug-coated balloons from the AcoArt I trial. J Vasc Surg. 2021; 74(3):756-762.e3. DOI: 10.1016/j.jvs.2021.01.041. View

Falkowski A, Bogacki H, Szemitko M . Assessment of Mortality and Factors Affecting Outcome of Use of Paclitaxel-Coated Stents and Bare Metal Stents in Femoropopliteal PAD. J Clin Med. 2020; 9(7). PMC: 7408889. DOI: 10.3390/jcm9072221. View

Schneider P, Laird J, Doros G, Gao Q, Ansel G, Brodmann M . Mortality Not Correlated With Paclitaxel Exposure: An Independent Patient-Level Meta-Analysis of a Drug-Coated Balloon. J Am Coll Cardiol. 2019; 73(20):2550-2563. DOI: 10.1016/j.jacc.2019.01.013. View

Tepe G, Schroeder H, Albrecht T, Reimer P, Diehm N, Baeriswyl J . Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial. J Endovasc Ther. 2020; 27(2):276-286. DOI: 10.1177/1526602820907917. View

Bittl J, He Y, Baber U, Feldman R, von Mering G, Kaul S . Bayes Factor Meta-Analysis of the Mortality Claim for Peripheral Paclitaxel-Eluting Devices. JACC Cardiovasc Interv. 2019; 12(24):2528-2537. DOI: 10.1016/j.jcin.2019.09.028. View

Dake M, Ansel G, Jaff M, Ohki T, Saxon R, Smouse H . Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011; 4(5):495-504. DOI: 10.1161/CIRCINTERVENTIONS.111.962324. View

Nowakowski P, Uchto W, Hrycek E, Kachel M, Ludyga T, Polczyk F . Microcrystalline paclitaxel-coated balloon for revascularization of femoropopliteal artery disease: Three-year outcomes of the randomized BIOPAC trial. Vasc Med. 2021; 26(4):401-408. DOI: 10.1177/1358863X20988360. View

Dake M, Ansel G, Jaff M, Ohki T, Saxon R, Smouse H . Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial. Circulation. 2016; 133(15):1472-83. PMC: 4823823. DOI: 10.1161/CIRCULATIONAHA.115.016900. View

Beckman J, White C . Paclitaxel-Coated Balloons and Eluting Stents: Is There a Mortality Risk in Patients With Peripheral Artery Disease?. Circulation. 2019; 140(16):1342-1351. DOI: 10.1161/CIRCULATIONAHA.119.041099. View

10.

Bjorkman P, Auvinen T, Hakovirta H, Romsi P, Turtiainen J, Manninen H . Drug-Eluting Stent Shows Similar Patency Results as Prosthetic Bypass in Patients with Femoropopliteal Occlusion in a Randomized Trial. Ann Vasc Surg. 2018; 53:165-170. DOI: 10.1016/j.avsg.2018.04.014. View

11.

Rocha-Singh K, Duval S, Jaff M, Schneider P, Ansel G, Lyden S . Mortality and Paclitaxel-Coated Devices: An Individual Patient Data Meta-Analysis. Circulation. 2020; 141(23):1859-1869. PMC: 8029645. DOI: 10.1161/CIRCULATIONAHA.119.044697. View

12.

Peach G, Griffin M, Jones K, Thompson M, Hinchliffe R . Diagnosis and management of peripheral arterial disease. BMJ. 2012; 345:e5208. DOI: 10.1136/bmj.e5208. View

13.

Miura T, Miyashita Y, Soga Y, Hozawa K, Doijiri T, Ikeda U . Drug-Eluting Versus Bare-Metal Stent Implantation With or Without Cilostazol in the Treatment of the Superficial Femoral Artery. Circ Cardiovasc Interv. 2018; 11(8):e006564. DOI: 10.1161/CIRCINTERVENTIONS.118.006564. View

14.

Katsanos K, Spiliopoulos S . Safety of Paclitaxel-Eluting Stents in Below-the-Knee Arteries for Critical Limb Ischemia Treatment: the Devil is in the Details. Cardiovasc Intervent Radiol. 2020; 43(12):1889-1890. DOI: 10.1007/s00270-020-02651-x. View

15.

Klumb C, Lehmann T, Aschenbach R, Eckardt N, Teichgraber U . Benefit and risk from paclitaxel-coated balloon angioplasty for the treatment of femoropopliteal artery disease: A systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. 2019; 16:42-50. PMC: 6890981. DOI: 10.1016/j.eclinm.2019.09.004. View

16.

Kinstner C, Lammer J, Willfort-Ehringer A, Matzek W, Gschwandtner M, Javor D . Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial. JACC Cardiovasc Interv. 2016; 9(13):1386-92. DOI: 10.1016/j.jcin.2016.04.012. View

17.

Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M . The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014; 7(1):10-9. DOI: 10.1016/j.jcin.2013.05.022. View

18.

Iida O, Soga Y, Urasawa K, Saito S, Jaff M, Wang H . Drug-coated balloon versus uncoated percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery: 2-year results of the MDT-2113 SFA Japan randomized trial. Catheter Cardiovasc Interv. 2019; 93(4):664-672. PMC: 6594002. DOI: 10.1002/ccd.28048. View

19.

Ipema J, Huizing E, Schreve M, de Vries J, Unlu C . Editor's Choice - Drug Coated Balloon Angioplasty vs. Standard Percutaneous Transluminal Angioplasty in Below the Knee Peripheral Arterial Disease: A Systematic Review and Meta-Analysis. Eur J Vasc Endovasc Surg. 2020; 59(2):265-275. DOI: 10.1016/j.ejvs.2019.10.002. View

20.

Kasapis C, Henke P, Chetcuti S, Koenig G, Rectenwald J, Krishnamurthy V . Routine stent implantation vs. percutaneous transluminal angioplasty in femoropopliteal artery disease: a meta-analysis of randomized controlled trials. Eur Heart J. 2008; 30(1):44-55. DOI: 10.1093/eurheartj/ehn514. View